ADA Standards of Care 2025 – Retinopathy, Neuropathy & Foot Care

Diabetic Retinopathy (DR)

• Highly specific neuro-vascular complication in both T1D & T2D.
• Prevalence tightly linked to duration of diabetes & quality of glycemic management.
• Leading cause of new-onset blindness among adults $20–74$ y in developed nations.
• Extra-ocular disorders (glaucoma, cataract) occur earlier & more often in people with DM.

Major Modifiable Risk Factors

• Chronic hyper-glycemia
• Hypertension
• Dyslipidemia
• Nephropathy / albuminuria

Key Evidence & Effect Sizes

• Intensive near-normoglycemia ➜ ↓ incidence & progression of DR, ↓ ocular surgery, ↑ self-reported vision (DCCT, UKPDS, ACCORD Eye, ETDRS).
• GLP-1 RA CVOT meta-analysis: no intrinsic DR-risk signal, but rapid $\Delta A1C$ at $3$ mo & $12$ mo associates with transient worsening.
• Liraglutide, semaglutide, dulaglutide: case reports/ RCT signals of mild early worsening; need longer trials including established DR cohorts.

Recommendations (Grade)

• 12.1 Achieve glycemic goals ⇒ slow DR (A)
• 12.2 Control BP & lipids ⇒ slow DR (A)

Screening Algorithms

• 12.3 T1D: first dilated comprehensive eye exam within $5$ y of diagnosis (B).
• 12.4 T2D: first exam at diagnosis (B).
• 12.5 No DR & on-target glycemia: screen $q1–2$ y; any DR → at least yearly, more if progressing (B).
• 12.6 Tele-retinal photography or FDA-authorized AI (AEYE-DS, EyeArt, LumineticsCore) acceptable if referral pathways exist (B).
• 12.7 Women of child-bearing potential with pre-existing DM: counsel on DR risk pre-conception & during pregnancy (B).
• 12.8 Pre-existing DM & pregnancy: exam pre-pregnancy + 1st trimester; then each trimester & $1$ y postpartum PRN severity (B).

Pregnancy-Specific Data

• Meta-analysis of $18$ studies: early-pregnancy DR prevalence $52.3\%$ ; PDR $6.1\%$ .
• Progression per $100$ pregnancies: new DR $15.0$ , progression NPDR $31.0$ , NPDR➜PDR $6.3$ , worsening PDR $37.0$ .
• Rapid glycemic tightening can transiently worsen DR.
• High-risk PDR/macular edema: prompt pan-retinal photocoagulation (PRP) before/early pregnancy; anti-VEGF (FDA cat C) only if maternal benefit > fetal risk.

Treatment Pathway

• 12.9 Refer any macular edema, mod-severe NPDR, or any PDR to experienced ophthalmologist (A).
• 12.10 PRP reduces severe vision loss in high-risk PDR & some severe NPDR (A).
• 12.11 Intravitreous anti-VEGF (aflibercept, ranibizumab) reasonable PRP alternative (A).
• 12.12 Anti-VEGF = first-line for center-involved DME w/ ↓VA (A).
• 12.13 Grid/focal laser or intravitreal steroids for refractory DME or anti-VEGF-ineligible eyes (A).
• 12.14 Aspirin for CVD prevention is NOT contraindicated (A).

Comparative Efficacy Highlights

• PRP (DRS, ETDRS): ↓ severe vision loss $15.9 \rightarrow 6.4\%$ .
• Anti-VEGF vs PRP for PDR: non-inferior VA, ↓ visual-field loss, ↓ vitrectomy, ↓ incident DME (DRCR Protocol S, CLARITY).
• DME drug choice: aflibercept superior to bevacizumab when baseline VA $\le 20/50$ (Protocol T).
• Good VA $\ge 20/25$ + DME: observation reasonable (Protocol V).

Adjunctive Systemic Management

• BP lowering helpful; targets <140/90 suffice (no added benefit <120 systolic).
• Fenofibrate slows progression esp. early DR.
• Emerging: GLP-1 RA portfolio linked to ↓ intraocular pressure & ↓ glaucoma incidence.

Vision Rehabilitation (12.15–12.16)

• ≈ $12\%$ of U.S. adults w/ DM have vision impairment.
• Refer to low-vision rehab; provide DSSME materials tailored to impaired vision.

Diabetic Neuropathy (DN)

• Heterogeneous disorders: distal symmetric polyneuropathy (DSPN = DPN), autonomic neuropathy (cardiac, GI, GU, sudomotor, etc.).
• Up to $50\%$ of DPN asymptomatic ⇒ annual screen essential.

Screening & Diagnosis (Grades)

• 12.17 Assess DPN at T2D diagnosis & $5$ y after T1D onset, then yearly (B).
• 12.18 Exam: history + small-fiber tests (temperature or pin-prick) + large-fiber tests (128-Hz tuning fork) + $10$ -g monofilament; monofilament annually for foot-ulcer risk (B).
• 12.19 Autonomic Sx review & signs beginning as above; ask about orthostatic dizziness, gastroparesis, ED, sweating changes (E).

Key Testing Nuggets

• LOPS = absent $10$ -g monofilament + ≥1 other abnormal neurologic test → high ulcer risk.
• Electrophysiology reserved for atypical presentations (asymmetry, acute onset, motor > sensory).
• Always rule out B $_{12}$ deficiency, toxins, CIDP, etc.

Treatment & Prevention

• 12.20 Optimize glycemia (T1D A; T2D C), weight, BP, lipids ⇒ prevent/slow DN (B).
• 12.21 Treat neuropathic pain & autonomic Sx to ↑QoL (B/E).
• 12.22 First-line analgesics: gabapentinoids, SNRIs, TCAs, sodium-channel blockers (A).
◦ Opioids (incl. tramadol/tapentadol) discouraged (B).

Evidence Corner

• Glycemic benefit strongest in T1D (DCCT/EDIC: $\approx 60\%$ DN risk ↓).
• ACCORD: intensive glucose + BP ↓ CAN by $25\%$ .
• Obesity weight loss (Look AHEAD) ↓ DN Sx. Bariatric surgery shows promise; more trials needed.
• Dyslipidemia & HTN independently raise DPN odds ratio $\approx 1.6$ .
• Exercise meta-analyses → modest symptom & function gains.

Pharmacologic Pain Details

• Gabapentinoids: pregabalin (strong RCTs), gabapentin; caution sedation/edema esp. elderly.
• SNRIs: duloxetine (2 HQ RCTs), venlafaxine.
• TCAs: amitriptyline effective but anticholinergic; avoid >65 y.
• Na-channel blockers: lamotrigine, lacosamide, carbamazepine, etc.
• Topicals: $8\%$ capsaicin patch (FDA-approved), 0.075 % cream, lidocaine 5 % patch (limited area, $\le12$ h/d).
• Combination therapy often superior (OPTION-DM trial).

Autonomic Sub-types & Management Pearls

• CAN: early ↓ HRV; late resting HR >100 bpm, orthostatic ↓SBP >20 mmHg. Manage Sx; emphasizes BP control.
• Orthostatic hypotension: non-pharm (fluid/salt, compression) + midodrine or droxidopa; bedtime short-acting antihypertensives for supine HTN.
• Gastroparesis: r/o obstruction; small-particle diet; hold opioids, GLP-1 RA if severe; metoclopramide ≤ $12$ wk; domperidone (ex-U.S.), erythro $\le2$ wk.
• ED: manage hypogonadism + PDE5 i or devices; female sexual dysfunction common – address libido, lubrication.
• Neurogenic bladder: evaluate recurrent UTI, residuals; consider urology.

Foot Care & Limb Preservation

• Ulcer & amputation risk stems from neuropathy, PAD, deformity, poor glycemia.
• Comprehensive foot exam annually; more often if risk present.

Key Recommendations

• 12.23 Annual comprehensive foot eval (A).
• 12.24 Exam elements: skin, deformity, neurologic (monofilament + one other), vascular (pulses) (B).
• 12.25 LOPS or prior ulcer/amp → inspect every visit (A).
• 12.26 Take history of ulcer, Pad, smoking, Charcot, retinopathy, CKD (B).
• 12.27 PAD screen: pulses, cap-refill, rubor, pallor, venous fill. Symptoms/signs ⇒ ABI + toe pressures & vascular referral (B).
• 12.28 Inter-professional foot team (podiatry ± vascular, endo, ID) for ulcers/high-risk feet (B).
• 12.29 Smokers or prior LE complications ⇒ specialist surveillance & smoking cessation counseling (B/A).
• 12.30 Daily self-inspection education for all; mirror technique for LOPS (B).
• 12.31 Therapeutic footwear for high-risk (LOPS, deformity, PAD, past ulcer) (B).
• 12.32 Chronic DFU non-responsive after $\ge 4$ wk optimal care → consider evidence-based advanced agents (NPWT, placental membrane, bioengineered skin, acellular matrices, platelet patches, topical oxygen) (A).

Risk Stratification (IWGDF 2023)

| Category | Ulcer Risk | Characteristics | Exam Frequency |
|0|Very Low|No LOPS, no PAD| $\text{q12 mo}$ |
|1|Low|LOPS or PAD| $6–12$ mo|
|2|Moderate|LOPS + PAD, or LOPS + deformity| $3–6$ mo|
|3|High|LOPS/PAD + prior ulcer/amp or ESRD| $1–3$ mo|

PAD Nuances

• Toe systolic <30 mmHg predicts poor healing. • Non-compressible vessels make ABI misleading; rely on toe pressures & pulse-volume recording. • Routine non-invasive studies for all DM >50 y every $5$ y recommended (SVS/APMA).

Education & Behavior

• Knowledge alone insufficient; needs ongoing reinforcement.
• Address barriers: vision, cognition, mobility; involve caregivers.
• Footwear: avoid barefoot; rocker soles, met-pads, extra-depth shoes; orthoses ↓ peak plantar pressure but RCT data on ulcer prevention limited.

Off-loading & Surgical Options

• Gold-standard plantar ulcer off-load: total-contact cast or removable cast walker.
• Deformity (Charcot, bunion, hammertoe) often needs surgical correction to prevent recurrence.
• Acute warm swollen foot w/o ulcer? Rule-out Charcot; immediate X-ray + non-weight-bearing + urgent referral.

Advanced Wound Therapies (evidence hierarchy)

NPWT – deep wounds, graft prep (Blume 2008 RCT).
Oxygen:
• Hyperbaric – mixed data; maybe neuro-ischemic DFU.
• Topical oxygen (continuous, cyclical, low-pressure) – multiple RCTs & meta-analyses show ↑ healing at $12$ wk.
Bio-engineered/allogenic tissues: bilayered skin, fibroblast matrices.
Acellular matrices: porcine UBM, fish skin, placental-derived, etc.
Growth factors: becaplermin $0.01\%$ gel.
Autologous PRP / fibrin-leukocyte patches.
Biophysical: electrical stimulation, shock-wave (evidence weaker).

Post-Healing

• Enroll in comprehensive prevention program: footwear review, bi-monthly surveillance, metabolic optimization, smoking cessation.

Cross-Cutting Principles & Ethical / Practical Implications

• Early detection via technology (AI retinal screening) improves equity where ophthalmology scarce.
• Inter-professional care ↓ amputations, hospitalizations, costs.
• Counsel on rapid A1C drops → transient DR worsening; personalize speed of intensification.
• Avoid chronic opioids; address mental health & sleep in neuropathic pain.
• Smoking, social determinants (access to shoes, low-vision aids) critically shape outcomes; integrate social work & coverage advocacy.
• Data sharing: document & relay all eye/foot exam results to primary team for closed-loop care quality.